Sign In
Buy AMPH
$18.12
-0.330 (-1.79%)
At Close: Jun 03, 2026
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Assembly Biosciences (NASDAQ:ASMB)
01:30am, Monday, 20'th Oct 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
10:41am, Friday, 17'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround
10:36am, Friday, 17'th Oct 2025
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
After Protracted Sell-Off, Amphastar Looks Like A Value Pick
10:06am, Tuesday, 23'rd Sep 2025
Amphastar Pharmaceuticals is rated a buy due to strong Q2 earnings, value metrics, and promising pipeline developments. AMPH beat revenue and EPS estimates in Q2, with BAQSIMI sales up 21% YoY, offset
Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?
09:51am, Tuesday, 02'nd Sep 2025
Investors need to pay close attention to AMPH stock based on the movements in the options market lately.
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
06:00am, Thursday, 28'th Aug 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be par
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
01:38pm, Tuesday, 12'th Aug 2025
On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.'s AMPH Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, an
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
06:00am, Monday, 11'th Aug 2025
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with ch
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
10:40am, Friday, 08'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript
01:40am, Friday, 08'th Aug 2025
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Commu
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say
06:31pm, Thursday, 07'th Aug 2025
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
06:15pm, Thursday, 07'th Aug 2025
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.94 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
04:05pm, Thursday, 07'th Aug 2025
- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 31'st Jul 2025
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
